Production vaccines of Modern Coronavirus at a plant in the Spanish pharmaceutical company Rovi could be resumed following an initial assessment, the European Union’s Drug Regulatory Authority (EMA) said on Friday as it continued its investigation into the contamination.
It is reminded that yesterday, Thursday, Japan suspends 1.63 million doses of Moderna vaccine, which were delivered to 863 vaccination centers across the country, more than a week after the local distribution company, Takeda Pharmaceutical, received reports of infection in some vials.
The infection detected in a lot distributed in Japan is believed to be due to a metal particle, reported the Japanese public television NHS, citing sources in the Ministry of Health.
According to Reuters, the EU drug regulator has stated that it is investigating the incident at the Spanish plant managed by Rovi, but that it sees no reason to seek a temporary suspension of production after an initial evaluation.
“Production of COVID-19 vaccines at Rovi can continue, after a preliminary risk assessment“, The European Medicines Agency said in a statement to the news agency.
“An investigation into the root cause is ongoing. The EMA will be able to provide more information depending on the progress of the investigation, “the regulator added.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
